DU12BBZ
Brachytherapy Uterus to None with Palladium 103 (Pd-103), Low Dose Rate (LDR) Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | D Radiation Therapy |
| Body System | U Female Reproductive System |
| Operation | 1 Brachytherapy |
| Body Part | 2 Uterus |
| Approach | B Low Dose Rate (LDR) |
| Device | B Palladium 103 (Pd-103) |
| Qualifier | Z None |
Procedure Overview
Brachytherapy for the female reproductive system involves placing a radioactive source directly inside or immediately adjacent to reproductive tissue - most commonly the cervix or uterus, and sometimes the vagina - so radiation is delivered from within the body rather than through it. Applicators are inserted, often under anesthesia and with imaging or exam guidance, and then loaded with a radioactive source for a defined period before removal.
This is a cornerstone of curative treatment for cervical cancer, typically given as a boost after a course of external beam radiation to concentrate additional dose directly into the tumor bed while limiting exposure to the bladder and rectum nearby. It's also used for some endometrial and vaginal cancers, particularly to treat the vaginal cuff after surgery or to manage disease confined to a small, accessible area.
Because the source sits in direct contact with or very near the target tissue, brachytherapy can deliver a dose intensity that external beams alone can't safely achieve, which is why it plays such a central role in gynecologic cancer treatment protocols despite requiring more invasive placement than beam therapy.
Anatomy & Axis Detail
Uterus
Brachytherapy to the uterus places radioactive sources within the endometrial cavity, most often using an intrauterine tandem or specialized applicator, to treat endometrial carcinoma or to boost the uterine corpus as part of cervical cancer treatment that extends into the uterine body. The uterine cavity's shape and depth vary between patients, particularly with prior childbirth or fibroids, so applicator selection and insertion depth must be individualized, and imaging is used to confirm proper placement before source loading. This intracavitary approach concentrates dose within the uterine walls while sharply reducing exposure to adjacent bowel and bladder compared to external delivery, and is typically performed adjunctively rather than as a sole treatment modality.
Modality Qualifier: Low Dose Rate (LDR)
Low Dose Rate (LDR) denotes brachytherapy using a source of lower activity that remains implanted or applied over an extended period, from many hours to a few days, exploiting continuous low-level irradiation for tumor control. This differs from High Dose Rate (HDR), which compresses the same general goal into brief, higher-intensity sessions, and LDR is often chosen for permanent seed implants such as certain prostate treatments.
Isotope: Palladium 103 (Pd-103)
Palladium-103 is another low-dose-rate isotope used in permanent interstitial seed implants, chiefly for prostate brachytherapy, but its shorter half-life (about 17 days) delivers its therapeutic dose faster than I-125. Clinicians may favor it for higher-grade or faster-growing tumors where a more concentrated early dose is desired, while I-125 remains preferred for lower-risk, slower disease.
Coding & Documentation
The documentation needs to identify the specific structure treated - cervix, uterus, vagina - and confirm that a radioactive source was placed in or against that tissue, distinguishing the procedure from external beam radiation aimed at the same organs. Operative and radiation oncology notes describing applicator insertion (such as a tandem and ovoid or ring applicator) followed by source loading support this code, and coders should verify whether the applicator placement and the radiation delivery were documented as one episode or need separate capture per facility convention.
A frequent error is coding the applicator insertion procedure without also capturing the radiation delivery itself, or the reverse, when documentation describes them as distinct steps. Coders should also confirm the correct body part when the applicator spans multiple structures, since a tandem and ovoid system treats the uterus and vagina together but the primary target documented by the physician should guide code selection.